MicroRNAs are very promising targets for diagnosis and prognosis of human pathologies. In addition, therapeutic molecules mimicking miRNA biological activity, or molecules inhibiting miRNA (antagomiRNAs) represent important tools for novel strategies to control and modify gene expression in eukaryotic systems, in vitro and in vivo. Therefore, miRNAs are key target in Teranostics. Among the molecules studied for “miRNA Therapeutics”, they are designed to mimic (miRNA replacement therapy) or to interfere with (antagomiRNA-based therapy) miRNA activity. Patents, patents applications and ongoing clinical trials based on miRNA targeting demonstrate the interest on this field of investigation for technology transfer.
MicroRNA "Theranostics": technology transfer and clinical trials
GAMBARI, Roberto
2014
Abstract
MicroRNAs are very promising targets for diagnosis and prognosis of human pathologies. In addition, therapeutic molecules mimicking miRNA biological activity, or molecules inhibiting miRNA (antagomiRNAs) represent important tools for novel strategies to control and modify gene expression in eukaryotic systems, in vitro and in vivo. Therefore, miRNAs are key target in Teranostics. Among the molecules studied for “miRNA Therapeutics”, they are designed to mimic (miRNA replacement therapy) or to interfere with (antagomiRNA-based therapy) miRNA activity. Patents, patents applications and ongoing clinical trials based on miRNA targeting demonstrate the interest on this field of investigation for technology transfer.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
